Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003033552 | SCV003320556 | uncertain significance | X-linked myopathy with postural muscle atrophy | 2022-02-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with FHL1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.008%). This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 161 of the FHL1 protein (p.His161Arg). |
Ambry Genetics | RCV004617153 | SCV005115890 | uncertain significance | Cardiovascular phenotype | 2024-04-19 | criteria provided, single submitter | clinical testing | The p.H161R variant (also known as c.482A>G), located in coding exon 3 of the FHL1 gene, results from an A to G substitution at nucleotide position 482. The histidine at codon 161 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |